

## Index

24-hour ambulatory pH-metry, 761

Abate, M.L. *see* Gaia, S.

Abenavoli, L. *see* Addolorato, G.

Abenavoli, L. *see* Leggio, L.

absenteeism and presenteeism, 459

acceptability, 657

acetaminophen, 29

achalasia, 431

Achkar, J.P. *see* Stevens, T.

acid suppression, 195, 423

acid, 517, 975

Ackroyd, R. *see* Kelty, C.J.

actigraphy, 969

acupuncture, 831

acute hepatitis C, 15

Adachi, K. *see* Amano, Y.

Adachi, K. *see* Fujisawa, T.

Adam, V. *see* Barkun, A.N.

Addolorato, G. *see* Leggio, L.

Addolorato, G., De Lorenzi, G., Abenavoli, L., Leggio, L., Capristo, E. & Gasbarrini, G. Psychological support counselling improves gluten-free diet compliance in coeliac patients with affective disorders, 777

adefovir, 993

adenocarcinoma, 1125

ADH, 109

adherence, 1071

adolescents, 295

adverse effects, 917

adverse events, 859, 1071

Aeed, H. *see* Levine, A.

aetiology, 1195

Afzal, N.A., van der Zaag-Loonen, H.J., Arnaud-Battandier, F., Davies, S., Murch, S., Derkx, B., Heuschkel, R. & Fell, J.M. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition, 167

age, 697, 1053

Agrawal, N. *see* Goldstein, J.L.

Ahlbom, H. *see* Wilder-Smith, C.H.

Alain, S. *see* De Saussure, P.

alarm symptoms, 1045

alcoholic liver cirrhosis, 437

almagat, 683

alosetron, 223

Amano, Y., Ishihara, S., Kushiyama, Y., Yuki, T., Takahashi, Y., Chinuki, D., Miyake, T., Miyaoka, Y., Rumi, M.A.K., Ishimura, N., Adachi, K. & Kinoshita, Y. Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage, 793

aminosalicylates, 143, 151

amitriptyline, 689

amylase, 173

anaemia, 917

Anderloni, A. *see* Parente, F.

Anderson, M. *see* Tsai, H.H.

Andersson, T. *see* Katz, P.O.

Andriulli, A. *see* Annese, V.

Andriulli, A. *see* Pilotto, A.

anicteric, 15

Annese, V., Piepoli, A., Perri, F., Lombardi, G., Latiano, A., Napolitano, G., Corritore, G., Vandewalle, P., Poulain, D., Colombel, J.F. & Andriulli, A. Anti-*Saccharomyces cerevisiae* mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features, 1143

Annichiaroco, B.E. & Siciliano, M. Pegylated interferon- $\alpha$ 2b monotherapy for haemodialysis patients with chronic hepatitis C, 123

anorectal and behavioral therapy, 667

antibiotics, 1181

antimicrobials, 675

anti-*Saccharomyces cerevisiae* antibodies (ASCA), 1143

antisecretory agents, 321

antisecretory drugs, 683

anti-ulcer medication, 577

antiviral therapy, 931

anxiety and depression, 803

anxiety, 89

apoptosis, 793

Arakawa, Y. *see* Kato, K.

Armstrong, D. *see* Bardhan, K.D.

Armstrong, D. *see* Fallone, C.A.

Armstrong, D., Talley, N.J., Lauritsen, K., Mour, B., Lind, T., Tunturi-Hihala, H., Venables, T., Green, J., Bigard, M.A., Mössner, J. & Junghard, O. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole, 413

Arnaud-Battandier, F. *see* Afzal, N.A.

arousals, 1153

ascites, 271

Aspinall, R.J. & Pockros, P.J. Review article: the management of side-effects during therapy for hepatitis C, 917

aspirin, 645, 1091

assessment, 89

Attwell, A., Ludkowsky, M., Nash, R. & Kugelmas, M. Treatment of Budd-Chiari syndrome in a Liver Transplant Unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation, 867

Austin, P. *see* Fallone, C.A.  
*autoantibodies*, 129, 231  
*autoimmunity*, 129  
 Avigan, M. *see* Brinker, A.  
 Avni, Y. *see* Levine, A.  
*azathioprine*, 65, 143, 151, 161, 843  
*azithromycin*, 295  
 Azumi, T. *see* Fujisawa, T.

*Bacillus clausii*, 1181  
 Badiola, C. *see* Rey, E.  
 Bajaj, J.S. *see* Sacian, K.  
 Balaguer, F. *see* Mata, A.  
*balloon size*, 431  
 Barbon, V. *see* Gaia, S.  
 Bardak, E. *see* Kulkarni, K.  
 Bardhan, K.D., Forbes, A., Marsden, C.L., Mason, T. & Short, G.  
     The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study, 213  
 Bardhan, K.D., Stanghellini, V., Armstrong, D., Berghöfer, P., Gatz, G. & Mönnikes, H. International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease, 891  
 Bardou, M. *see* Barkun, A.N.  
 Barkun, A.N. *see* Fallone, C.A.  
 Barkun, A.N., Herba, K., Adam, V., Kennedy, W., Fallone, C.A. & Bardou, M. The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding, 195  
*barostat*, 689, 975  
 Barrado, A. *see* Salgueiro, J.  
*Barrett's epithelium*, 793  
*Barrett's oesophagus*, 637, 645, 705, 719, 1083, 1125  
 Barril, G., Quiroga, J.A., Sanz, P., Rodriguez-Salvanés, F., Selgas, R. & Carreño, V. Pegylated interferon- $\alpha$ 2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers, 37  
 Barth, J. *see* Vakil, N.  
*basic Fibroblast Growth Factor (bFGF)*, 585  
 Bastens, B. *see* Delwaide, J.  
 Bastida, G. *see* Doménech, E.  
 Bathgate, A.J. *see* Younger, H.M.  
 Bebb, J.R. & Scott, B.B. Systematic review: how effective are the usual treatments for ulcerative colitis? 143, 151  
 Beck, A. *see* Delvaux, M.  
 Beglinger, C. *see* Lesbros-Pantolickova, D.  
 Behrens, C. *see* Raedler, A.  
 Belaiche, J. *see* Franchimont, N.  
 Bellissant, E. *see* Siproudhis, L.  
 Bengtsson, C. *see* Tindberg, Y.  
 van den Berg, A.P. *see* Weersma, R.K.  
 Berghöfer, P. *see* Bardhan, K.D.  
 Bergmans, P. *see* de Wit, N.J.  
 Berman, B. *see* Sung, J.J.Y.  
 Bermejo, F. *see* Lopez-Sanroman, A.  
 Bernabucci, V. *see* Gatta, L.  
 Betterle, C. *see* Briani, C.

Bharucha, A.E., Locke III, G.R., Seide, B.M. & Zinsmeister, A.R. A new questionnaire for constipation and faecal incontinence, 355  
 Bianchi Porro, G. *see* Parente, F.  
 Bias, P. *see* Raedler, A.  
 Bicheler, V. *see* Bruley des Varannes, S.  
*bifidobacteria*, 1133  
 Bigard, M.A. *see* Armstrong, D.  
*bioequivalence*, 407  
*biofeedback*, 539, 667  
 Birani, C. *Reply*, 821  
 Bishehsari, F. *see* Mikaeli, J.  
 Blacka, J., Donoghue, J., Sutherland, M., Martincich, L., Mitten-Lewis, S., Morris, P. & Meredith, G. Dwell time and functional failure in percutaneous endoscopic gastrostomy tubes: a prospective randomized-controlled comparison between silicon polymer and polyurethane percutaneous endoscopic gastrostomy tubes, 875  
 Blennow, M. *see* Tindberg, Y.  
*blood flow*, 517  
 Blum, A.L. *see* Bytzer, P.  
 Blum, A.L. *see* Lesbros-Pantolickova, D.  
*BMI*, 223  
 Boaz, M. *see* Levine, A.  
 Boccio, J. *see* Salgueiro, J.  
 Bochenek, W. *see* Richter, J.E.  
 Bochenek, W.J., Mack, M.E., Fraga, P.D. & Metz, D.C. Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis, 1105  
*body mass index*, 497  
 de Boer, W.A. *see* de Wit, N.J.  
 Bolus, R. *see* Labus, J.S.  
 Bonaz, B. *see* Bruley des Varannes, S.  
 Bondarop, P. *see* Wilder-Smith, C.H.  
*bone metabolism*, 607  
 Bonnot-Marlier, S. *see* Bruley des Varannes, S.  
 Boparai, V. *see* Gerson, L.B.  
 Bordas, J.M. *see* Mata, A.  
 Borgia, M.C. *see* Consolazio, A.  
 Bost, R. *see* Bruley des Varannes, S.  
 Bott, C., Rudolph, M.W., Schneider, A.R.J., Schirrmacher, S., Skalsky, B., Peterit, H.-U., Langguth, P., Dressman, J.B. & Stein, J. *In vivo* evaluation of a novel pH- and time-based multiunit colonic drug delivery system, 347  
 Bouhnik, Y. *see* de Saussure, P.  
 Boulton-Jones, J.R., Fenn, R.M.F., West, J., Logan, R.F.A. & Ryder, S.D. Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls, 551  
 Bourgeois, N. *see* Delwaide, J.  
 Bouzamondo, H. *see* Delvaux, M.  
 Bovenschen, H.J., Laheij, R.J.F., Tan, A.C.I.T.L., Wittman, E.M., van Rossum, L.G.M. & Jansen, J.B.M.J. Health-related quality of life of patients with gastrointestinal symptoms, 311  
*bowel ultrasound*, 959  
*bowel wall behaviour*, 959  
 Bracco, A. *see* Reilly, M.C.  
 Braden, B. *see* Kerber, A.  
*breakthrough*, 281

*breath tests*, 347

Briani, C., Ruggero, S., Zara, G., Toffanin, E., Ermani, M., Betterle, C. & Guariso, G. Anti-ganglioside antibodies in children with coeliac disease: correlation with gluten-free diet and neurological complications, 231

Brignoli, R. *see* Melzer, J.

Brinker, A. & Avigan, M. Epidemiology of ischaemic colitis, 697

Brisinda, G., Cadeddu, F., Mabisombi, A. & Maria, G. Author's reply, 123

Brown, G.R. *see* Getachew, Y.

Brown, N.J. *see* Kelty, C.J.

Browning, J.D. *see* Getachew, Y.

Bruley des Varannes, S., Gharib, H., Bicheler, V., Bost, R., Bonaz, B., Stanescu, L., Delchier, J.C. & Bonnot-Marlier, S. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects, 899

Bruzzone, E., Raia, V., Gaudiello, G., Polito, G., Buccigrossi, V., Formicola, V. & Guarino, A. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration, 813

Brzezinski, A. *see* Stevens, T.

Buccigrossi, V. *see* Bruzzone, E.

*Budd-Chiari syndrome*, 867

budesonide, 745

Buell, D. *see* Pettengell, K.

Bunnapradist, S. *see* Fabrizi, F.

Buss, D.C. *see* Ingram, J.R.

butyrate, 1133

Bytzer, P. *see* Madsen, L.G.

Bytzer, P., Blum, A., De Herdt, D., Dubois, D. & on behalf of the trial investigators Six-month trial of on-demand rabeprazole 10mg maintains symptom relief in patients with non-erosive reflux disease, 181

Bytzer, P. & Blum, A.L. Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease, 389

<sup>13</sup>C-breath test, 109

<sup>13</sup>C-urea, 1001

Cadeddu, F. *see* Brisinda, G.

Cadeddu, F. *see* Brisinda, G.

calprotectin, 615

Cameron, A.J. *see* Nandurkar, S.

Cammarota, G. *see* Nista, E.C.

Campbell, M.S. & Reddy, K.R. Review article: the evolving role of liver biopsy, 249

cancer screening, 381

cancer, 445

Candelli, M. *see* Nista, E.C.

candidiasis, 475

Capristo, E. *see* Addolorato, G.

capsule endoscopy, 1083

Card, T.R. *see* West, J.

Card, T.R., West, J. & Holmes, G.K.T. Risk of malignancy in diagnosed coeliac disease: a 24-year prospective, population-based, cohort study, 769

Cardenas, A., Kelleher, T. & Chopra, S. Review article: hepatic hydrothorax, 271

cardiac chest pain, 909

cardiovascular, 51

Carnicer, F. *see* Zapater, P.

Carreño, V. *see* Barril, G.

Carrera, E. *see* Lopez-Sanroman, A.

Cascavilla, L. *see* Pilotto, A.

case control, 497

Caspary, W.F. *see* Kerber, A.

Casswall, T.H. *see* Tindberg, Y.

Castell, D.O. *see* Katz, P.O.

Cazzato, L.A. *see* Nista, E.C.

celiac disease, 73, 231

cerebral hypoperfusion, 821

Chan, A.O.O. *see* Gu, Q.

Chan, C.K. *see* Wong, W.M.

Chan, F.K.L. *see* Sung, J.J.Y.

Chan, F.K.-L. *see* Wong, V.W.-S.

Chan, H.L.-Y. *see* Wong, V.W.-S.

Chan, K.-F. *see* Wong, V.W.-S.

Chan, L.S. *see* Sung, J.J.Y.

Chand, N., Johnson, D.A., Tabangin, M. & Ware, J.C. Sleep dysfunction in patients with gastro-oesophageal reflux disease: prevalence and response to GERD therapy, a pilot study, 969

Chang, L. *see* Labus, J.S.

change in diagnoses, 803

Chapman, R. *see* Tsai, H.H.

Chen, A., Li, C.-N., Hsu, P.-I., Lai, K.-H., Tseng, H.-H., Hsu, P.-N., Lo, G.-H., Lo, C.-C., Lin, C.-K., Hwang, I.-R., Yamaoka, Y. & Chen, H.-C. Risks of interleukin-1 genetic polymorphisms and *Helicobacter pylori* infection in the development of gastric cancer, 203

Chen, H.-C. *see* Chen, A.

Chen, J.D.Z. *see* Ouyang, H.

Chen, Y. *see* Katz, P.O.

chest pain, 909

Cheung, H.K.-L. *see* Gu, Q.

Chiba, N. *see* Fallone, C.A.

children, 167, 295

Childs, S. *see* Raghunath, A.S.

Ching, J.Y.L. *see* Sung, J.J.Y.

Chinuki, D. *see* Amano, Y.

Chiu, Y.-L. *see* Kovacs, T.O.G.

choice, 989

Chopra, S. *see* Cardenas, A.

chronic hepatitis C, 1189

ciclosporin, 143

Ciociola, A.A. *see* Rodriguez-Stanley, S.

cirrhosis, 29, 271

Claessens, G. *see* Pierik, M.

clarithromycin, 99

Clark, W. *see* Marshall, J.K.

coagulation, 289

coeliac disease, 769, 777, 821

cohort study, 577, 751

Colin, P. *see* Konstan, M.W.

colitis, 697

collagenous colitis, 745

Collette, J. *see* Franchimont, N.

Collins, S.M. for the WEL Investigators *see* Marshall, J.K.

Colombel, J.F. *see* Annese, V.

colon, 983

colonic diseases functional, 1195

colonoscopy, 381, 507

colorectal cancer, 507, 1115

combination interferon and ribavirin therapy, 629

comorbidity, 1195

conclusions, 567

Consolazio, A., Borgia, M.C., Ferro, D., Iacopini, F., Paoluzi, O.A., Crispino, P., Nardi, F., Rivera, M. & Paoluzi, P. Increased thrombin generation and circulating levels of tumour necrosis factor- $\alpha$  in patients with chronic *Helicobacter pylori*-positive gastritis, 289

constipation, 355

Contos, M.J. *see* Sterling, R.K.

controlled release, 347

coronary heart disease, 289

Corrigan, B.W. *see* Koch, K.M.

Corritore, G. *see* Annese, V.

cost effectiveness, 593

cost, 657

cost-benefit analysis, 939

cost-benefit, 321

cost-effectiveness, 195

COX-2 expression, 793

COX-2 inhibitors, 1035

COX-2 selective inhibitors, 321, 527

Cremonini, F. *see* Nista, E.C.

Crispino, P. *see* Consolazio, A.

Crohn's disease, 151, 167, 483, 585, 607, 843, 951, 959, 1019, 1143

current depression, 777

cyclooxygenase, 675

cyclooxygenase-2 inhibitor, 51

CYP1A2, 223

cystic fibrosis, 813

D'Angelo, C. *see* Leggio, L.

Dahab, S.T. *see* Khuroo, M.S.

Dalhoff, K. *see* Schmidt, L.E.

Daneli, P.G. *see* Parente, F.

Daniel, J. *see* Sacian, K.

Davies, S. *see* Afzal, N.A.

Davila, J.A. *see* Rabeneck, L.

Davis, K.J., Kumar, D. & Poloniecki, J. Adjuvant biofeedback following anal sphincter repair: a randomized study, 539

daytime/nighttime heartburn, 1105

De Herdt, D. *see* Bytzer, P.

De Lorenzi, G. *see* Addolorato, G.

De Maeght, S. *see* Delwaide, J.

De Micheli, E. *see* Frazzoni, M.

De Vos, M. *see* Franchimont, N.

decision analysis, 939

deficiency, 1029

Degl'Innocenti, A. *see* Fallone, C.A.

Delchier, J.C. *see* Bruley des Varannes, S.

Delvaux, M., Beck, A., Jacob, J., Bouzamondo, H., Weber, F.T. & Frexinos, J. Effect of asimadoline, a  $\kappa$  opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome, 237

Delwaide, J., Bourgeois, N., Gérard, C., De Maeght, S., Mokaddem, F., Wain, E., Bastens, B., Fevery, J., Géhenot, M., Le Moine, O., Martinet, J.P., Robaeys, G., Servais, B., Van Gossum, M., Van Vlierberghe, H. & The Belgian Association for the Study of the Liver (BASL) Treatment of acute hepatitis C with interferon  $\alpha$ -2b: early initiation of treatment is the most effective predictive factor of sustained viral response, 15

Dent, J. *see* Ruiz-Gómez, A.

depression, 917

Derkx, B. *see* Afzal, N.A.

DeVault, K.R. *see* Wolfsen, H.C.

DeWitt, J.E. *see* Feyen, B.

Di Giuda, D. *see* Leggio, L.

Di Mario, F. *see* Pilotto, A.

diabetic gastroparesis, 333

diagnosis, 469, 1001, 1063

dialysis, 1053

dialyzer pore size, 37

Díaz-Rubio, M. *see* Rey, E.

Dickason, J. *see* Fischbach, L.A.

Diehl, A.M. *see* Nair, S.

diet, 231, 497

Dikici, B. *see* Özgenç, F.

Dinasquet, M. *see* Siproudhis, I.

disease outcome, 483

distal ulcerative colitis, 783

Dixit, V. *see* Fabrizi, F.

Dolwani, S., Metzner, M., Wassell, J.J., Yong, A. & Hawthorne, A.B. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology, 615

Domènech, E., Hinojosa, J., Esteve-Comas, M., Gomollón, F., Herrera, J.M., Bastida, G., Obrador, A., Ruiz, R., Saro, C., Gassull, M.A. & Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECU) Granulocyteapheresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study, 1347

Donoghue, J. *see* Blacka, J.

dosage forms, 883

dose escalation, 65

double-blind, 295

Drapers, J.A.G. *see* West, R.L.

Dressman, J.B. *see* Bott, C.

Drossman, D.A. *see* Whitehead, W.E.

Dubois, D. *see* Bytzer, P.

DuBois, S. & Kowdley, K.V. Review article: targeted screening for hereditary haemochromatosis in high-risk groups, 1

Duggan, C. *see* Konstan, M.W.

Duggan, S. *see* Tsai, H.H.

Dulai, G. *see* Fabrizi, F.

van Dullemen, H.M. *see* Weersma, R.K.

duodenal disorder, 413

duodenal ulcer, 733

duodenum, 517

dyspepsia classification, 1171

dyspepsia, 99, 469, 1171

Easley, K. *see* Stevens, T.  
*echinocandin*, 475  
*efficacy*, 783, 1071  
 Eghtesad, B. *see* Neff, G.W.  
 Ehksam, E. *see* Hawkey, C.J.  
 Eigen, H. *see* Konstan, M.W.  
 Eisen, G.M. *see* Eliakim, R.  
 Eisen, G.M. *see* Goldstein, J.L.  
*elderly*, 1115  
 El-Dika, S. *see* Fallone, C.A.  
*electroacupuncture*, 831  
 Eliakim, R., Yassin, K., Shlomi, I., Suissa, A. & Eisen, G.M. A novel diagnostic tool for detecting oesophageal pathology: the PillCam oesophageal video capsule, 1083  
 El-Serag, H. *see* Kulkarni, K.  
 El-Serag, H.B. *see* Rabeneck, L.  
 Emmanuel, A.V. *see* Rayner, C.K.  
*endoscopic therapy*, 195  
*endoscopy surveillance*, 1125  
*endoscopy*, 989, 1083  
 ENRD, 657  
*enteral nutrition*, 167  
*Enzyme-Linked Immunosorbent Assay (ELISA)*, 585  
*epidemiology*, 73, 373, 483, 551, 697, 719, 751, 769  
*eradication*, 733  
 Ermani, M. *see* Briani, C.  
*eruptive oesophagitis*, 883  
*erythropoietin*, 437  
 Eslick, G.D. & Talley, N.J. Non-cardiac chest pain: predictors of health care seeking, the types of health care professional consulted, work absenteeism and interruption of daily activities, 909  
*esomeprazole*, 399, 413, 657, 969, 1099  
 Esteban, A. *see* Zapater, P.  
 Esteve-Comas, M. *see* Domènech, E.  
*ethanol metabolism*, 109  
*ethnic differences*, 705  
*Eudragit*<sup>®</sup>, 347  
*EuroQol*, 311  
 Evans, B.K. *see* Ingram, J.R.  
*exercise*, 497  
*extrahepatic manifestations*, 129  
 Fabrizi, F., Martin, P., Dixit, V., Bunnapradist, S. & Dulai, G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis, 1271  
 Fabrizi, F., Martin, P., Dixit, V., Bunnapradist, S. & Dulai, G. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease, 1053  
 Fabrizi, F. & Martin, P. Author's reply: 123  
 Facklam, D. *see* Pettengell, K.  
 Fadda, M. *see* Gaia, S.  
 Fallone, C.A. *see* Barkun, A.N.  
 Fallone, C.A., Barkun, A.N., Mayrand, S., Wakil, G., Friedman, G., Szilagyi, A., Wheeler, C. & Ross, D. There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with *Helicobacter pylori*, 761  
 Fallone, C.A., Guyatt, G.H., Armstrong, D., Wiklund, I., Degl'Innocenti, A., Heels-Ansdell, D., Barkun, A.N., Chiba, N., van Zanten, S.J.O., El-Dika, S., Austin, P., Tanser, L. & Schünemann, H.J. Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease? 1161  
*famotidine*, 559  
 Färkkilä, M.A. *see* Hillilä, M.T.  
 Farkouh, M. *see* Hawkey, C.J.  
 Farr Jr, G.H. *see* Nair, S.  
 Farup, P.G. *see* Vandvik, P.O.  
*fatty liver*, 45  
*fecal calprotectin*, 813  
*fecal incontinence*, 355, 539, 667  
*feeling thermometer*, 1161  
 Feld, A.D. *see* Whitehead, W.E.  
 Fell, J.M. *see* Afzal, N.A.  
 Felt-Bersma, R.J.F. *see* West, R.L.  
 Fendrick, A.M. *see* Vrijen, S.  
 Fenn, R.M.F. *see* Boulton-Jones, J.R.  
 Fennerty, M.B. *see* Lee, T.J.  
 Ferlitsch, A. *see* Homoncik, M.  
 Fernández-Esparrach, G. *see* Mata, A.  
 Ferro, D. *see* Consolazio, A.  
 Fett, S. *see* Nandurkar, S.  
 Feu, F. *see* Mata, A.  
 Fevery, J. *see* Delwaide, J.  
 Feyen, B., Wall, G.C., Finnerty, E.P., DeWitt, J.E. & Reyes, R.S. Meta-analysis: budesonide treatment for collagenous colitis, 745  
 Feyerabend, C. *see* Ingram, J.R.  
 Fiasse, R. *see* Franchimont, N.  
 Fincke, C. *see* Harrison, S.A.  
 Finnerty, E.P. *see* Feyen, B.  
 Fischbach, L.A., van Zanten, S.V. & Dickason, J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-*Helicobacter pylori* quadruple therapies, 1071  
*fistulas*, 585  
*fluoxetine*, 689  
*focal liver lesion*, 249  
 Forbes, A. *see* Bardhan, K.D.  
 Formicola, V. *see* Bruzzese, E.  
 Forrest, K., Symmons, D. & Foster, P. Systematic review: Is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? 1035  
 Foster, G.R. Review article: Pegylated interferons: chemical and clinical differences, 825  
 Foster, P. *see* Forrest, K.  
*fracture*, 551  
 Fraga, P. *see* Richter, J.E.  
 Fraga, P.D. *see* Bochenek, W.J.  
 Frances, R. *see* Zapater, P.  
 Franceschi, F. *see* Nista, E.C.  
 Franceschi, M. *see* Pilotto, A.  
 Franchimont, D. *see* Franchimont, N.  
 Franchimont, N., Putzeys, V., Collette, J., Vermeire, S., Rutgeerts, P., De Vos, M., Van Gossum, A., Franchimont, D., Fiasse, R., Pelckmans, P., Malaise, M., Belaiche, J. & Louis, E. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease, 607  
 Franco, J. *see* Saeian, K.

Fransen, G.A.J., Janssen, M.J.R., Muris, J.W.M., Laheij, R.J.F. & Jansen, J.B.M.J. Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy, 1045

Frazzoni, M., De Micheli, E., Zentilin, P. & Savarino, V. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn, 81

Freston, J.W., Kukulka, M.J., Lloyd, E. & Lee, C. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube, 407

Frexinos, J. *see* Delvaux, M.

Fried, M. *see* Lesbros-Pantollickova, D.

Friedman, G. *see* Fallone, C.A.

Fueyo, A. *see* Rey, E.

Fujisawa, T., Adachi, K., Komazawa, Y., Mihara, T., Azumi, T., Katsube, T., Furuta, K., Kazumori, H. & Kinoshita, Y. *Helicobacter pylori* infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists, 559

Fulcher, A.S. *see* Sterling, R.K.

*functional dyspepsia*, 365, 423

*functional gastrointestinal disorders*, 831

*functional heartburn*, 81, 975

Fung, J. *see* Neff, G.W.

Furuta, K. *see* Fujisawa, T.

Gaffney, D. *see* Winter, J.

Gaia, S., Marzano, A., Smedile, A., Barbon, V., Abate, M.L., Olivero, A., Lagget, M., Paganin, S., Fadda, M., Niro, G. & Rizzetto, M. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B, 281

Gallus, S. *see* Parente, F.

*game therapy*, 381

*ganglioside*, 231

Gao, Q., van Hogenzand, R.A., Lamers, C.B.H.W. & Verspaget, H.W. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease, 585

García Rodríguez, L.A. *see* Ruigómez, A.

García-Buey, L. *see* Medina, J.

García-Plaza, A. *see* López-Sanromán, A.

Gardner, J.D., Sloan, S., Robinson, M. & Miner Jr, P.B. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor, 1381

Gardner, J.D., Sloan, S., Robinson, M. & Miner, P.B. Oesophageal pH has a power-law distribution in control and gastro-oesophageal reflux disease subjects, 1373

Garg, A.X. *see* Marshall, J.K.

Gasbarrini, A. *see* Nista, E.C.

Gasbarrini, G. *see* Addolorato, G.

Gasbarrini, G. *see* Leggio, L.

Gasbarrini, G. *see* Nista, E.C.

Gassull, M.A. *for the Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU)* *see* Domènech, E.

*gastroprotection*, 1091

*gastric alcalinization*, 683

*gastric cancer*, 261, 1045

*gastric disorder*, 413

*gastric emptying*, 333

*gastric myoelectrical activity*, 831

*gastric pH*, 683

*gastritis*, 109

*gastrointestinal bleeding*, 195, 321

*gastrointestinal endoscopy*, 381

*gastrointestinal hemorrhage*, 381

*gastrointestinal motility*, 831

*gastrointestinal oncology*, 983

*gastrointestinal symptom rating scale (GSRS)*, 761, 891

*gastrointestinal symptoms*, 311

*gastrointestinal transit*, 347

*gastrointestinal*, 51

*gastrointestinal endoscopy*, 939

*gastro-oesophageal reflux disease*, 81, 389, 399, 451, 567, 637, 705, 719, 761, 803, 891, 909, 969, 1083, 1105, 1153, 1161

*gastro-oesophageal reflux*, 733, 751

*gastroscopy*, 989

Gatta, L., Perna, F., Ricci, C., Osborn, J.F., Tampieri, A., Bernabucci, V., Miglioli, M. & Vaira, D. A rapid immunochromatographic assay for *Helicobacter pylori* in stool before and after treatment, 469

Gatz, G. *see* Bardhan, K.D.

Gaudiello, G. *see* Bruzese, E.

Géhénot, M. *see* Delwaide, J.

Geldof, H. *see* de Wit, N.J.

*general practice*, 751, 1195

*geographical differences*, 705

Gérard, C. *see* Delwaide, J.

Gerson, L.B., Boparai, V., Ullah, N. & Triadaflopoulos, G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors, 637

Getachew, Y., Browning, J.D., Prebis, M., Rogers, T. & Brown, G.R. Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation, 629

Charib, H. *see* Bruley des Varannes, S.

Ghosh, S. *see* Winter, T.A.

Giles, N. *see* Russo, A.

Ginés, A. *see* Mata, A.

Gisbert, J.P. & Pajares, J.M. Review article: <sup>13</sup>C-urea breath test in the diagnosis of *Helicobacter pylori* infection, 1001

Gitton, X. *see* Hawkey, C.J.

*gluten*, 231

*gluten-free diet*, 777, 821

Goldman, C. *see* Salgueiro, J.

Goldstein, J.L., Eisen, G.M., Agrawal, N., Stenson, W.F., Kent, J.D. & Verburg, K.M. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib, 527

Gomollón, F. *see* Domènech, E.

Goodgame, R. *see* Kulkarni, K.

Gorard, D.A. *see* Olithselvan, A.

Gordon, C., Kang, J.Y., Neild, P.J. & Maxwell, J.D. Review article: the role of the hiatus hernia in gastro-oesophageal reflux disease, 719

*graded method*, 431

Graffner, H. *see* Ruigómez, A.  
 Granström, M. *see* Tindberg, Y.  
*granulocyte and monocyte adsorptive apheresis*, 783  
*granulomatosis diseases*, 1019  
 Greco, S. *see* Parente, F.  
 Green, J. *see* Armstrong, D.  
 Greenwood, R. *see* Tobias, J.H.  
 Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU) *see* Domènech, E.  
 Gu, Q., Xia, H.H.-X., Wang, W.H., Wang, J.D., Wong, W.M., Chan, A.O.O., Yuen, M.F., Lam, S.K., Cheung, H.K.-L., Liu, X.G. & Wong, B.C.-Y. Effect of cyclo-oxygenase inhibitors on *Helicobacter pylori* susceptibility to metronidazole and clarithromycin, 675  
 Guarino, A. *see* Buzzese, E.  
 Guariso, G. *see* Briani, C.  
 Guda, N., Partington, S. & Vakil, N. Symptomatic gastro-oesophageal reflux, arousals and sleep quality in patients undergoing polysomnography for possible obstructive sleep apnoea, 1153  
 Guyatt, G.H. *see* Fallone, C.A.  
 van Haastert, M. *see* Weersma, R.K.  
 Hallas, J. *see* Lassen, A.  
 Hallerbäck, B. *see* Wilder-Smith, C.H.  
 Hansen, B.E. *see* West, R.L.  
 Harker, J. *see* Ramirez, F.C.  
 Harrison, S.A., Fincke, C., Helinski, D., Torgerson, S. & Hayashi, P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients, 623  
 Hart, A.L. *see* Rayner, C.K.  
 Hasunuma, O. *see* Kato, K.  
 Hawkey, C.J., Farkouh, M., Gitton, X., Ehksam, E., Huels, J. & Richardson, P. Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib – study design and patient demographics, 51  
 Hawthorne, A.B. *see* Dolwani, S.  
 Hayashi, P. *see* Harrison, S.A.  
 Hayes, P.C. *see* Younger, H.M.  
 Hayward, C.M.M. *see* Rayner, C.K.  
 Hayward, R.A. *see* Vijn, S.  
 Hazelhoff, B. *see* de Wit, N.J.  
 HBV, 281  
*health care seeking*, 909  
*health economics*, 939  
*health related quality of life*, 311, 1161  
*health service research*, 381, 939  
*healthy volunteers*, 689  
*heartburn*, 81, 181, 389, 413, 451, 705, 719  
 Heels-Ansdell, D. *see* Fallone, C.A.  
*Helicobacter pylori treatment*, 99  
*Helicobacter pylori*, 109, 117, 261, 289, 295, 381, 451, 469, 559, 675, 733, 761, 1001, 1029, 1071, 1181  
 Helinski, D. *see* Harrison, S.A.  
 Hemminger, L.L. *see* Wolfsen, H.C.  
*hemochromatosis*, 1  
*hemodialysis*, 37  
*hemolysis*, 1189  
 Hendrickse, M.T. *see* Tsibouris, P.  
*hepatic hydrothorax*, 271  
*hepatitis B immunoglobulin*, 993  
*hepatitis B virus*, 993, 1053  
*hepatitis B*, 249  
*hepatitis C virus infection*, 129  
*hepatitis C virus*, 931  
*hepatitis C*, 249, 445, 629, 917  
*hepatocellular carcinoma*, 445, 983  
 Herba, K. *see* Barkun, A.N.  
*herbals*, 1205  
 Herrera, J.M. *see* Domènech, E.  
 Herrlinger, K. *see* Kerber, A.  
 Heuschkel, R. *see* Afzal, N.A.  
*HFE gene*, 1  
*hiatus hernia*, 705, 719  
 Higgins, P.D.R. *see* Laine, L.  
 Hillilä, M.T. & Färkkilä, M.A. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population, 339  
 Hinojosa, J. *see* Domènech, E.  
 Ho, S. *see* Saeian, K.  
 Ho, Y.P. *see* Sung, J.J.Y.  
 Hodgson, T. *see* Leão, J.C.  
 Hofer, T.P. *see* Vijn, S.  
 Hogan, S.P. & Rothenberg, M.E. Review article: the eosinophil as a therapeutic target in gastrointestinal disease, 1231  
 van Hogezand, R.A. *see* Gao, Q.  
 Holland, J.F. *see* Ramirez, F.C.  
 Holmes, G.K.T. *see* Card, T.R.  
 Homann van der Heide, J.J. *see* Weersma, R.K.  
 Homoncik, M., Jilma-Stohlawetz, P., Schmid, M., Ferlitsch, A. & Peck-Radosavljevic, M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study, 437  
 Horga, J.F. *see* Zapater, P.  
*hormones*, 237  
 Horowitz, M. *see* Russo, A.  
 Howden, C.W. *see* Lee, T.J.  
 Hsu, P.-I. *see* Chen, A.  
 Hsu, P.-N. *see* Chen, A.  
 Hu, W.H.C. *see* Wong, W.M.  
 Huang, J.Q. *see* Wong, W.M.  
 Hubbard, R. *see* West, J.  
 Huels, J. *see* Hawkey, C.J.  
 Hui, A.Y. *see* Wong, V.W.-S.  
 Hui, W.M. *see* Wong, W.M.  
*human immunodeficiency virus*, 993  
 Hungin, A.P.S. *see* Raghunath, A.S.  
 Hwang, I.-R. *see* Chen, A.  
*hypercholesterolaemia*, 73  
*hypertension*, 73  
 Iacopini, F. *see* Consolazio, A.  
 IBS-C, 213  
*ibuprofen*, 51  
*icterus*, 15  
 Ihlebæk, C. *see* Vandvik, P.O.  
 Imaoka, A. *see* Kato, K.  
*immigration*, 445

immune complex deposition, 129  
*immunology and microbiology*, 303  
*immunomodulators*, 601  
 Inadomi, J. *see* Vijn, S.  
*index terms*, 883  
*indirect costs*, 459  
*inflammation*, 615  
*inflammatory bowel disease*, 65, 161, 303, 615, 951, 1035, 1143  
*inflammatory disorders*, 303, 593, 601, 607, 851, 859  
*infliximab*, 151, 303, 585, 607, 851  
 Ingram, J.R., Routledge, P., Rhodes, J., Marshall, R.W., Buss, D.C., Evans, B.K., Feyerabend, C. & Thomas, G.A.O. Nicotine enemas for treatment of ulcerative colitis: a study of the pharmacokinetics and adverse events associated with three doses of nicotine, 859  
 Innes, A. *see* Winter, T.A.  
*insulin resistance*, 23  
*intragastric pH*, 399  
*interferon*, 15, 917, 931, 1189  
*interferon- $\alpha$* , 129  
*international validation*, 891  
*intestinal disorders*, 237, 303, 339, 593, 601, 607, 851, 859  
*intestinal inflammation*, 813  
*intragastric acidity*, 899  
*intraluminal fungal colonization*, 875  
*intravenous*, 883, 1099  
*iron*, 1  
*irritable bowel syndrome*, 89, 213, 339, 459, 615, 1195, 1205  
 Isaacs, P.E.T. *see* Tsibouris, P.  
*ischaemic*, 697  
 Ishihara, S. *see* Amano, Y.  
 Ishii, H. *see* Suzuki, M.  
 Ishii, Y. *see* Kato, K.  
 Ishimura, N. *see* Amano, Y.  
 Iwasaki, A. *see* Kato, K.  
  
 Jacob, J. *see* Delvaux, M.  
 Jahnsen, J. *see* Winter, T.A.  
 James, C.D. *see* Koch, K.M.  
 Jansen, J.B.M.J. *see* Bovenschen, H.J.  
 Jansen, J.B.M.J. *see* Fransen, G.A.J.  
 Jansen, P.L.M. *see* Weersma, R.K.  
 Janssen, M.J.R. *see* Fransen, G.A.J.  
 Jilma-Stohlawetz, P. *see* Homoncik, M.  
 Johansson, S. *see* Ruigómez, A.  
 Johnson, D.A. *see* Chand, N.  
 Jones, K.L. *see* Russo, A.  
 Joossens, S. *see* Pierik, M.  
 Junghard, O. *see* Armstrong, D.  
  
 Kamm, M.A. *see* Rayner, C.K.  
 Kang, J.Y. *see* Gordon, C.  
 Kang, J.Y. Systematic review: geographical and ethnic differences in gastro-oesophageal reflux disease, 705  
 Kato, K., Mizuno, S., Umesaki, Y., Ishii, Y., Sugitani, M., Imaoka, A., Otsuka, M., Hasunuma, O., Kurihara, R., Iwasaki, A. & Arakawa, Y. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis, 1133  
  
 Katsube, T. *see* Fujisawa, T.  
 Katz, P.O., Castell, D.O., Chen, Y., Andersson, T. & Sostek, M.B. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study, 399  
 Kazumori, H. *see* Fujisawa, T.  
 KC11458, 333  
 Kelleher, T. *see* Cardenas, A.  
 Kelty, C.J., Ackroyd, R., Brown, N.J., Stephenson, T.J., Stoddard, C.J. & Reed, M.W.R. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation, 1289  
 Kennedy, W. *see* Barkun, A.N.  
 Kent, J.D. *see* Goldstein, J.L.  
 Kerber, A., Trojan, J., Herrlinger, K., Zgouras, D., Caspary, W.F. & Braden, B. The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study, 983  
 Kersey, K.E. *see* Koch, K.M.  
 Khuroo, M.S. *see* Khuroo, M.S.  
 Khuroo, M.S., Khuroo, M.S. & Dahab, S.T. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4, 931  
 Kinoshita, Y. *see* Amano, Y.  
 Kinoshita, Y. *see* Fujisawa, T.  
 Kitagawa, T. *see* Yamamoto, T.  
 Kluyts, T. *see* Pettengell, K.  
 Knox, J.F. *see* Sacian, K.  
 Koch, K.M., Corrigan, B.W., Manzo, J., James, C.D., Scott, R.J., Stead, A.G. & Kersey, K.E. Alosentron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors, 223  
 Komazawa, Y. *see* Fujisawa, T.  
 Konstan, M.W., Stern, R.C., Trout, J.R., Sherman, J.M., Eigen, H., Wagener, J.S., Duggan, C., Wohl, M.E.B. & Colin, P. Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy, 1365  
 Kovacs, T.O.G., Lee, C.Q., Chiu, Y.-L., Pilmer, B.L. & Metz, D.C. Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis, 883  
 Kowdley, K.V. *see* DuBois, S.  
 Krause, G. *see* Russo, A.  
 Kugelmas, M. *see* Attwell, A.  
 Kuipers, E.J. *see* West, R.L.  
 Kukulka, M.J. *see* Freston, J.W.  
 Kulasingam, S.L. *see* Orlando, L.A.  
 Kulkarni, K., Barcak, E., El-Serag, H. & Goodgame, R. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States, 445  
 Kumar, D. *see* Davis, K.J.  
 Kurihara, R. *see* Kato, K.  
 Kushiyama, Y. *see* Amano, Y.  
  
 Labus, J.S., Bolus, R., Chang, L., Wiklund, I., Naesdal, J., Mayer, E.A. & Naliboff, B.D. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale, 89

*lafutidine*, 559  
 Lagget, M. *see* Gaia, S.  
 Laheij, R.J.F. *see* Bovenschen, H.J.  
 Laheij, R.J.F. *see* Fransen, G.A.J.  
 Lai, K.C. *see* Wong, W.M.  
 Lai, K.-H. *see* Chen, A.  
 Laine, L. *see* Rubenstein, J.H.  
 Laine, L. & Higgins, P.D.R. Author's reply, 697  
 Lam, C.L.K. *see* Wong, W.M.  
 Lam, K.F. *see* Wong, W.M.  
 Lam, S.K. *see* Gu, Q.  
 Lam, S.K. *see* Wong, W.M.  
 Lamers, C.B.H.W. *see* Gao, Q.  
*lamivudine*, 993  
 Lanas, A. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract, 321  
 Langguth, P. *see* Bott, C.  
*lansoprazole*, 407, 657, 883  
 Lanza, F. *see* Vakil, N.  
 Lao, L. *see* Sung, J.J.Y.  
 Lashner, B. *see* Stevens, T.  
 Lassen, A., Hallas, J. & Schaffalitzky de Muckadell, O.B. Use of anti-secretory medication: a population-based cohort study, 577  
 Lasso de la Vega, M.C. *see* Zapater, P.  
 Latiano, A. *see* Annese, V.  
 Lau, W. *see* Pettengell, K.  
 Lauritsen, K. *see* Armstrong, D.  
 Lavergne-Slove, A. *see* de Saussure, P.  
 Le Moine, O. *see* Delwaide, J.  
 Leandro, G. *see* Pilotto, A.  
 Leão, J.C., Hodgson, T., Scully, C. & Porter, S. Review article: orofacial granulomatosis, 1019  
 Lee, C. *see* Freston, J.W.  
 Lee, C.Q. *see* Kovacs, T.O.G.  
 Lee, T.J., Fennerty, M.B. & Howden, C.W. Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? 1241  
 Leggio, L. *see* Addolorato, G.  
 Leggio, L., Abenavoli, L., D'Angelo, C., Di Giuda, D., Gasbarrini, G. & Addolorato, G. Gluten-related cerebral hypoperfusion and neurologic disorders in coeliac patients, 821  
 Leonardi, N. *see* Salgueiro, J.  
 Lesbros-Pantoflickova, D., Michetti, P., Fried, M., Beglinger, C. & Blum, A.L. Meta-analysis: the treatment of irritable bowel syndrome, 1253  
 Leung, F.W. *see* Ramirez, F.C.  
 Leung, W.K. *see* Sung, J.J.Y.  
 Levine, A., Shevah, O., Shabat-Schayek, V., Aeed, H., Boaz, M., Moss, S.F., Niv, Y., Avni, Y. & Shirin, H. Masking of  $^{13}\text{C}$  urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole, 117  
 Levy, R.L. *see* Whitehead, W.E.  
 Li, C.-N. *see* Chen, A.  
 Liang, S.M. *see* Sung, J.J.Y.  
 Liew, C.-T. *see* Wong, V.W.-S.  
 Lin, C.-K. *see* Chen, A.  
 Lind, T. *see* Armstrong, D.  
 Liu, X.G. *see* Gu, Q.  
*liver biopsy*, 45, 249  
*liver descriptors*, 281, 623, 1189  
*liver failure*, 173  
*liver function test*, 45  
*liver transplantation*, 867, 993  
*liver*, 445  
 Llach, J. *see* Mata, A.  
 Lloyd, E. *see* Freston, J.W.  
 Lo, C.-C. *see* Chen, A.  
 Lo, G.-H. *see* Chen, A.  
 Locke III, G.R. *see* Bharucha, A.E.  
 Locke III, G.R. *see* Nandurkar, S.  
 Logan, R.F.A. *see* Boulton-Jones, J.R.  
 Logan, R.F.A. *see* West, J.  
 Lombardi, G. *see* Annese, V.  
 Longo, M.G. *see* Pilotto, A.  
 Lopez-Sanroman, A., Bermejo, F., Carrera, E. & Garcia-Plaza, A. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis, 161  
 Louis, E. *see* Franchimont, N.  
*lower oesophageal sphincter*, 719  
 Ludkowski, M. *see* Attwell, A.  
 Luketic, V.A. *see* Sterling, R.K.  
*lumiracoxib*, 51  
*lymphoma*, 769  
 Mabisombi, A. *see* Brisinda, G.  
 McIntyre, A.S. *see* Olithselvan, A.  
 Mack, M. *see* Richter, J.E.  
 Mack, M.E. *see* Bochenek, W.J.  
 McKee, D. *see* Sacian, K.  
 McKeith, D. *see* Tsai, H.H.  
 Madalinski, M. The treatment algorithm instead of the unknown optimal dose of botulinum toxin for chronic anal fissure, 123  
 Madsen, L.G., Wallin, L. & Bytzer, P. Identifying response to acid suppressive therapy in functional dyspepsia using a random starting day trial – is gastro-oesophageal reflux important? 423  
 Madsen, L.G. & Bytzer, P. Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial design, 365  
*maintenance therapy*, 181, 567  
*maintenance*, 213, 657  
 Malaise, M. *see* Franchimont, N.  
 Malekzadeh, R. *see* Mikaeli, J.  
 Malfertheiner, P. *see* Nardone, G.  
*malignancy*, 769, 1045  
 Manzo, J. *see* Koch, K.M.  
 Maria, G. *see* Brisinda, G.  
 Marsden, C.L. *see* Bardhan, K.D.  
 Marshall, J.K., Thabane, M., Garg, A.X., Clark, W., Meddings, J., Collins, S.M. & for the *the wel* Investigators. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, 1317  
 Marshall, R.W. *see* Ingram, J.R.  
 Martin, P. *see* Fabrizi, F.  
 Martincich, I. *see* Blacka, J.  
 Martinet, J.P. *see* Delwaide, J.

Martinez Sarrasague, M. *see* Salgueiro, J.  
 Maruyama, K. *see* Suzuki, M.  
 Marzano, A. *see* Gaia, S.  
 Mason, T. *see* Bardhan, K.D.  
 Mata, A., Bordas, J.M., Feu, F., Ginés, A., Pellisé, M., Fernández-Esparrach, G., Balaguer, F., Piqué, J.M. & Llach, J. Wireless capsule endoscopy in patients with obscure gastrointestinal bleeding: a comparative study with push enteroscopy. 189  
 Matchar, D.B. *see* Orlando, L.A.  
 Matsumoto, K. *see* Yamamoto, T.  
 Matuchansky, C. *see* de Saussure, P.  
 Maxwell, J.D. *see* Gordon, C.  
 Mayer, E.A. *see* Labus, J.S.  
 Mayrand, S. *see* Fallone, C.A.  
 Mazeran, M.-C. *see* de Saussure, P.  
 Meddings, J. *see* Marshall, J.K.  
*medical decision analysis*, 381  
*medical procedure*, 15  
*medical ritual*, 939  
 Medina, J., García-Buey, L. & Moreno-Otero, R. Review article: hepatitis C virus-related extra-hepatic disease — aetiopathogenesis and management. 129  
 Meineche-Schmidt, V. Classification of dyspepsia and response to treatment with proton-pump inhibitors. 1171  
*Melkerson Rosenthal syndrome*, 1019  
 Melzer, J., Rösch, W., Reichling, J., Brignoli, R. & Saller, R. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). 1279  
 Meredith, G. *see* Blacka, J.  
*meta-analysis*, 745, 1045, 1053, 1071  
*metabolic syndrome*, 45  
*metabolism*, 223  
*metabolites*, 601  
*metastasis*, 983  
*metformin*, 23  
*methotrexate hepatotoxicity*, 249  
*methotrexate*, 151  
 Metz, D.C. *see* Bochenek, W.J.  
 Metz, D.C. *see* Kovacs, T.O.G.  
 Metzner, M. *see* Dolwani, S.  
*micafungin*, 475  
 Michetti, P. *see* Lesbros-Pantoflickova, D.  
*micronutrient*, 1029  
 Miglioli, M. *see* Gatta, L.  
 Mihara, T. *see* Fujisawa, T.  
 Mikaeli, J., Bishehsari, F., Montazeri, G., Yaghoobi, M. & Malekzadeh, R. Pneumatic balloon dilatation in achalasia: a prospective comparison of safety and efficacy with different balloon diameters. 431  
 Mills, A.S. *see* Sterling, R.K.  
 Mills, P.R. *see* Winter, J.  
 Miner Jr, P.B. *see* Gardner, J.D.  
 Miner Jr, P.B. *see* Rodriguez-Stanley, S.  
 Miner, P.B. *see* Gardner, J.D.  
*minerals*, 1029  
 Mitten-Lewis, S. *see* Blacka, J.  
 Miyake, T. *see* Amano, Y.  
 Miyaoka, Y. *see* Amano, Y.  
 Mizuno, S. *see* Kato, K.  
 Mokadem, F. *see* Delwaide, J.  
*molecular alterations*, 261  
 Molteni, M. *see* Parente, F.  
 Mönnikes, H. *see* Bardhan, K.D.  
 Montazeri, G. *see* Mikaeli, J.  
 Moreno-Otero, R. *see* Medina, J.  
 Morris, P. *see* Blacka, J.  
 Moss, S.F. *see* Levine, A.  
 Mössner, J. *see* Armstrong, D.  
*motilin*, 333  
*motility and nerve-gut interactions*, 237, 339, 689  
 Moum, B. *see* Armstrong, D.  
*mucin-phenotype*, 793  
*mucosal healing*, 167  
*mucus secretion*, 517  
 Mukumoto, M. *see* Yamamoto, T.  
 Murch, S. *see* Afzal, N.A.  
 Muris, J.W.M. *see* Fransen, G.A.J.  
*mycophenolate mofetil*, 943  
 Mynhardt, J. *see* Pettengell, K.  
*myocardial infarction*, 73  
 Naesdal, J. *see* Labus, J.S.  
*nasogastric tube*, 407  
 Nair, S., Diehl, A.M., Wiseman, M., Farr Jr, G.H. & Perrillo, R.P. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. 23  
 Naliboff, B.D. *see* Labus, J.S.  
 Nandurkar, S., Locke III, G.R., Fett, S., Zinsmeister, A.R., Cameron, A.J. & Talley, N.J. Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community. 497  
 Napolitano, G. *see* Annese, V.  
*naproxen*, 51  
 Nardi, F. *see* Consolazio, A.  
 Nardone, G., Rocco, A. & Malferttheiner, P. Review article: *Helicobacter pylori* and molecular events in precancerous gastric lesions. 261  
*NASH*, 623  
 Nash, R. *see* Attwell, A.  
 Naumann, M. *see* Schröder, O.  
*nausea and vomiting*, 831  
*needle-stick*, 15  
 Neff, G.W., Sherman, K.E., Eghtesad, B. & Fung, J. Review article: current status of liver transplantation in HIV-infected patients. 993  
 Neild, P.J. *see* Gordon, C.  
*neurologic disorders*, 821  
*neuropathy*, 231  
*neutropenia*, 917  
*NG tube*, 407  
 Niazi, S. *see* Ozturk, R.  
*nicotine enema*, 859  
 Niro, G. *see* Gaia, S.  
 Niro, V. *see* Pilotto, A.  
 Nishimura, N. *see* Yamamoto, T.  
 Nista, E.C., Candelli, M., Cremonini, F., Cazzato, I.A., Zocco, M.A., Franceschi, F., Cammarota, G., Gasbarrini, G. & Gasbarrini, A. *Bacillus clausii* therapy to reduce side-effects of anti-*Helicobacter*

*pylori* treatment: randomized, double-blind, placebo controlled trial, 1181

*nitric oxide*, 813

Niv, Y. *see* Levine, A.

*non alcoholic steatohepatitis*, 23

*non-alcoholic fatty liver disease*, 249

*non-cardiac chest pain*, 909

*non-erosive gastro-oesophageal reflux disease*, 181

*non-erosive reflux disease*, 81, 389

*non-steroidal anti-inflammatory agents*, 373

*non-steroidal anti-inflammatory drugs*, 321, 517, 577, 645, 793, 1035, 1091

*obesity*, 623

Obrador, A. *see* Domènech, E.

*obscure gastrointestinol bleeding*, 189

*observer variation*, 1205

O'Donovan, D.G. *see* Russo, A.

*oesophageal adenocarcinoma*, 645

*oesophageal and gastric ambulatory pH monitoring*, 637

*oesophageal cancer*, 1045

*oesophageal capsule*, 1083

*oesophageal complications*, 751

*oesophageal disorder*, 413

*oesophagitis*, 567, 577

*oesophagus*, 975

Olithselvan, A., McIntyre, A.S. & Gorard, D.A. Are patients' sedation preferences at gastroscopy influenced by preceding patients' decisions? 989

Olivero, A. *see* Gaia, S.

*omeprazole*, 365, 423, 899, 1171

*on-demand dosing*, 181

*on-demand therapy*, 389

*on-demand*, 657

*onset and disappearance*, 803

Oostenbrug, L.E. *see* Weersma, R.K.

*orally disintegrating tablet*, 407

Orlando, L.A., Kulasingam, S.L. & Matchar, D.B. Meta-analysis: the detection of pancreatic malignancy with positron emission tomography, 1063

*orlistat*, 623

*oro-cecal-transit time*, 347

*orofacial granulomatosis*, 1019

Osborn, J.F. *see* Gatta, L.

*osteoporosis*, 851, 951

Otsuka, M. *see* Kato, K.

*outcome measure*, 891

Ouyang, H. & Chen, J.D.Z. Review article: therapeutic roles of acupuncture in functional gastrointestinal disorders, 831

Özgenç, F., Dikici, B. & Yagci, R.V. Letter to the Editors, 247

Ozturk, R., Niazi, S., Stessman, M. & Rao, S.S.C. Long-term outcome and objective changes of anorectal function after biofeedback therapy for faecal incontinence, 667

Paganin, S. *see* Gaia, S.

Pajares, J.M. *see* Gisbert, J.P.

Palazón, J.M. *see* Zapater, P.

Palsson, O.S. *see* Whitehead, W.E.

*pancreas*, 983

*pancreatic malignancy*, 1063

*pancreatitis*, 173, 843

*pantoprazole*, 567, 1105

Paoluzi, O.A. *see* Consolazio, A.

Paoluzi, P. *see* Consolazio, A.

*paracetamol*, 173

Parente, F., Sampietro, G.M., Molteni, M., Greco, S., Anderloni, A., Sposito, C., Danelli, P.G., Taschieri, A.M., Gallus, S. & Bianchi Porro, G. Behaviour of the bowel wall during the first year after surgery is a strong predictor of symptomatic recurrence of Crohn's disease: a prospective study, 959

Paris, F. *see* Piloito, A.

Partington, S. *see* Guda, N.

Pascual, S. *see* Zapater, P.

Peck-Radosavljevic, M. *see* Homoncik, M.

*pegylated interferon- $\alpha$* , 37, 129

Peine, C. *see* Sacian, K.

Pelckmans, P. *see* Franchimont, N.

*pellets*, 347

Pellisé, M. *see* Mata, A.

*peptic ulcer*, 99, 577, 1091

*percutaneous endoscopic gastrostomy tube*, 875

Pérez-Mateo, M. *see* Zapater, P.

Perna, F. *see* Gatta, L.

Perri, F. *see* Annese, V.

Perrillo, R.P. *see* Nair, S.

Petererit, H.-U. *see* Bott, C.

Peters, F.T.M. *see* Weersma, R.K.

Pettengell, K., Mynhardt, J., Kluyts, T., Lau, W., Facklam, D. & Buell, D. the FK463 South African Study Group. Successful treatment of oesophageal candidiasis by miconafungin: a novel systemic antifungal agent, 475

*pH monitoring*, 423, 559

*pharmacodynamics*, 399, 825, 883

*pharmacogenetics*, 593

*pharmacokinetics*, 29, 223, 399, 825, 859

*pH-dependent delivery*, 347

*photodynamic therapy*, 1125

*physician-patient correlation*, 1161

Piepoli, A. *see* Annese, V.

Pierik, M., Vermeire, S., Steen, K.V., Joossens, S., Claessens, G., Vlietinck, R. & Rutgeerts, P. Tumour necrosis factor- $\alpha$  receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab, 303

Pilmer, B.I. *see* Kovacs, T.O.G.

Pilotto, A., Franceschi, M., Leandro, G., Paris, F., Cascavilla, L., Longo, M.G., Niro, V., Andriulli, A., Scarcelli, C. & Di Mario, F. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs, 1091

Piqué, J.M. *see* Mata, A.

*placebo*, 365, 423

*platelet counts*, 437

*platelet reactivity*, 437

*pleurodesis*, 271

Ploeg, R.J. *see* Weersma, R.K.

PMMA, 37

*pneumatic dilatation*, 431

Pockros, P.J. *see* Aspinall, R.J.

*poisoning*, 173

Polito, G. *see* Bruzzese, E.

Poloniecki, J. *see* Davis, K.J.

*polyethylene glycol (PEG)*, 825

*polymethacrylates*, 347

*polyurethane*, 875

*population based*, 483

*porfimer sodium*, 1125

*portal hypertension*, 29, 271

Porter, S. *see* Leão, J.C.

*positron emission tomography*, 1063

Posthumus, M.D. *see* Weersma, R.K.

Poulain, D. *see* Annese, V.

Poves-Francés, C. *see* Rey, E.

Prebis, M. *see* Getachew, Y.

*prednisolone*, 951

*preference measures*, 1161

*preneoplastic lesions*, 261

*prevalence*, 719

*primary biliary cirrhosis*, 551

*primary care*, 451

*primary sclerosing cholangitis*, 943

Probert, C.S.J. *see* Tobias, J.H.

*probiotics*, 813, 1181

*prokinetic drugs*, 333

Proskin, H.M. *see* Rodriguez-Stanley, S.

*prospective*, 167

*proton pump inhibition*, 195

*proton pump inhibitor therapy*, 637

*proton pump inhibitors*, 117, 365, 389, 413, 423, 567, 733, 1091, 1171

*psychological general well being*, 761, 891

*psychological support counseling*, 777

*push enteroscopy*, 189

Putzeys, V. *see* Franchimont, N.

*QoLRAD*, 1161

*quadruple therapy*, 1071

*quality of life*, 167, 803, 1153

*questionnaire*, 355, 551

Quiroga, J.A. *see* Barril, G.

Rabeneck, L., Davila, J.A., Thompson, M. & El-Serag, H.B.  
Outcomes in elderly patients following surgery for colorectal cancer in the veterans affairs health care system, 1115

rabeproazole, 181, 451, 899

Raedler, A., Behrens, C. & Bias, P. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis – results from a randomized-controlled trial, 1353

Raghunath, A.S., Hungin, A.P.S., Wooff, D. & Childs, S.  
Systematic review: the effect of *Helicobacter pylori* and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis, 733

Raia, V. *see* Bruzzese, E.

Ramirez, F.C., Holland, J.F., Harker, J. & Leung, F.W.  
Effect of acid on duodenal blood flow and mucus secretion measured by reflectance spectrophotometry: a prospective, randomized-controlled study, 517

randomized controlled trial, 437, 527

randomized placebo-controlled trial, 1133

randomized trial, 365, 423

randomized, 295

ranitidine effervescent, 683

Rao, S.S.C. *see* Ozturk, R.

Rayner, C.K., Hart, A.L., Hayward, C.M.M., Emmanuel, A.V. & Kamm, M.A. Azathioprine dose escalation in inflammatory bowel disease, 65

receptors, 237

rectum, 689

Reddy, K.R. *see* Campbell, M.S.

Reed, M.W.R. *see* Kelty, C.J.

reflectance spectrophotometry, 517

reflux oesophagitis, 705, 719

reflux symptoms, 389

reflux, 497

regurgitation, 451, 705, 1105

Reichling, J. *see* Melzer, J.

Reilly, M.C., Bracco, A., Ricci, J.-F., Santoro, J. & Stevens, T. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire – irritable bowel syndrome version (WPAL:IBS), 459

relative risk, 931

reliability, 891

reproducibility, 365

ReQuest<sup>TM</sup>, 891

resistance, 675

response, 365

retreatment, 213

review, 1001

Rey, E., Poves-Francés, C., Sánchez, G., Fueyo, A., Badiola, C. & Díaz-Rubio, M. Effects of effervescent ranitidine on gastric pH: comparison with almagate and placebo in fasting and postprandial conditions, 683

Reyes, R.S. *see* Feyen, B.

Reymann, J.M. *see* Siproudhis, L.

Rhodes, J. *see* Ingram, J.R.

ribavirin, 129, 917, 1189

Ricci, C. *see* Gatta, L.

Ricci, J.-F. *see* Reilly, M.C.

Richardson, P. *see* Hawkey, C.J.

Richter, J.E., Fraga, P., Mack, M., Bochenek, W., Sabesin, S.M. & the Pantoprazole US GERD Study Group. Prevention of erosive oesophagitis relapse with pantoprazole, 567

Rivera, M. *see* Consolazio, A.

Rizzetto, M. *see* Gaia, S.

Robaeys, G. *see* Delwaide, J.

Robinson, M. *see* Gardner, J.D.

Rocco, A. *see* Nardone, G.

Rodriguez-Salvánés, F. *see* Barril, G.

Rodriguez-Stanley, S., Ciocia, A.A., Zubaidi, S., Proskin, H.M. & Miner Jr, P.B. A single dose of ranitidine 150mg modulates oesophageal acid sensitivity in patients with functional heartburn, 975

Rogers, T. *see* Getachew, Y.

Röhss, K. *see* Wilder-Smith, C.H.

Rome classification, 1171

Rome criteria, 339

Rösch, W. *see* Melzer, J.  
 Rosen, J.P. *see* Tsai, H.H.  
 Ross, D. *see* Fallone, C.A.  
 van Rossum, L.G.M. *see* Bovenschen, H.J.  
 Rothenberg, M.E. *see* Hogan, S.P.  
 Round, P. *see* Winter, T.A.  
 Routledge, P. *see* Ingram, J.R.  
 Rubenstein, J.H. & Laine, L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. 373  
 Rudolph, M.W. *see* Bott, C.  
 Ruggero, S. *see* Briani, C.  
 Ruigómez, A., García Rodríguez, L.A., Wallander, M.-A., Johansson, S., Graffner, H. & Dent, J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. 751  
 Ruiz, R. *see* Domènech, E.  
 Rumi, M.A.K. *see* Amano, Y.  
 Russel, M.G.V.M. *see* Ryan, B.M.  
 Russel, M.G.V.M. *see* Wolters, F.L.  
 Russo, A., Stevens, J.E., Giles, N., Krause, G., O'Donovan, D.G., Horowitz, M. & Jones, K.L. Effect of the motilin agonist KC 11458 on gastric emptying in diabetic gastroparesis. 333  
 Rutgeerts, P. *see* Franchimont, N.  
 Rutgeerts, P. *see* Pierik, M.  
 Ryan, B.M., Russel, M.G.V.M., Schurgers, L., Wicher, M., Sijbrandij, J., Stockbrugger, R.W. & Schoon, E. Effect of antitumour necrosis factor- $\alpha$  therapy on bone turnover in patients with active Crohn's disease: a prospective study. 851  
 Ryder, S.D. *see* Boulton-Jones, J.R.  
 Sabesin, S.M. *see* Richter, J.E.  
 Saeian, K., Bajaj, J.S., Franco, J., Knox, J.F., Daniel, J., Peine, C., McKee, D., Varma, R.R., Ho, S. & and Midwest Hepatitis Study Group. High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard  $\alpha$ -interferon and ribavirin. 1189  
 safety, 51, 783  
 Salgueiro, J., Zubillaga, M., Goldman, C., Barrado, A., Martínez-Sarrasague, M., Leonardi, N. & Boccio, J. Review article: is there a link between micronutrient malnutrition and *Helicobacter pylori* infection? 1029  
 Saller, R. *see* Melzer, J.  
 Salvatori, J.J. *see* Sterling, R.K.  
 Sampietro, G.M. *see* Parente, F.  
 Sánchez, G. *see* Rey, E.  
 Santoro, J. *see* Reilly, M.C.  
 Sanyal, A.J. *see* Sterling, R.K.  
 Sanz, P. *see* Barril, G.  
 Saro, C. *see* Domènech, E.  
 Sasi, M.R. *see* Tobias, J.H.  
 satisfaction, 657  
 de Saussure, P., Lavergne-Slove, A., Mazeran, M.-C., Alain, S., Matuchansky, C. & Bouhnik, Y. A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease. 1323  
 Savarino, V. *see* Frazzoni, M.  
 scale, 891  
 Scarcelli, C. *see* Pilotto, A.  
 Schaffalitzky de Muckadell, O.B. *see* Lassen, A.  
 Schirrmacher, S. *see* Bott, C.  
 Schmid, M. *see* Homoncik, M.  
 Schmidt, L.E. & Dalhoff, K. Hyperamylasaemia and acute pancreatitis in paracetamol poisoning. 173  
 Schneider, A.R.J. *see* Bott, C.  
 Schoon, E. *see* Ryan, B.M.  
 Schröder, O., Naumann, M. & Stein, J. Anti-*Saccharomyces cerevisiae* antibodies and response to infliximab in refractory Crohn's disease. 821  
 Schünemann, H.J. *see* Fallone, C.A.  
 Schurgers, L. *see* Ryan, B.M.  
 Schwartz, H. *see* Vakil, N.  
 Scott, B.B. *see* Bebb, J.R.  
 Scott, R.J. *see* Koch, K.M.  
 screening, 1, 507  
 Scully, C. *see* Leão, J.C.  
 Sébille, V. *see* Siproudhis, L.  
 secondary care, 451  
 sedation, 989  
 Seide, B.M. *see* Bharucha, A.E.  
 Selgas, R. *see* Barril, G.  
 sensation, 831  
 sensitivity, 975  
 Servais, B. *see* Delwaide, J.  
 severity, 355  
 Shabat-Shayek, V. *see* Levine, A.  
 Shapiro, D. *see* Winter, J.  
 Shepherd, A. *see* Tsai, H.H.  
 Sherman, J.M. *see* Konstan, M.W.  
 Sherman, K.E. *see* Neff, G.W.  
 Shevah, O. *see* Levine, A.  
 Schiffman, M.L. *see* Sterling, R.K.  
 Shirin, H. *see* Levine, A.  
 Shlomi, I. *see* Eliakim, R.  
 Short, G. *see* Bardhan, K.D.  
 Siciliano, M. *see* Annicchiaroco, B.E.  
 side effects, 843, 1181  
 Sijbrandij, J. *see* Ryan, B.M.  
 silicone, 875  
 single subject trials, 365, 423  
 Siproudhis, L., Dinasquet, M., Sébille, V., Reymann, J.M. & Bellissant, E. Differential effects of two types of antidepressants, amitriptyline and fluoxetine, on anorectal motility and visceral perception. 689  
 site specific delivery, 347  
 Skalsky, B. *see* Bott, C.  
 sleep disorders, 1153  
 sleep, 969  
 Sloan, S. *see* Gardner, J.D.  
 Smedile, A. *see* Gaia, S.  
 Smith, C. *see* West, J.  
 Smout, A.J.P.M. *see* de Wit, N.J.  
 Sonnenberg, A. Personal view: 'Don't ask, don't tell' – the undesirable consequences of incidental test results in gastroenterology. 381  
 Sonnenberg, A. Personal view: cost and benefit of medical rituals in gastroenterology. 939

Sörberg, M. *see* Tindberg, Y.  
 Sostek, M.B. *see* Katz, P.O.  
*Spechler's disease activity index*, 761  
*sphincter repair*, 539  
*spontaneous bacterial empyema*, 271  
 Spooner, R.J. *see* Winter, J.  
 Sposito, C. *see* Parente, F.  
*standard gamble*, 1161  
 Stanescu, L. *see* Bruley des Varannes, S.  
 Stanghellini, V. *see* Bardhan, K.D.  
*state anxiety*, 777  
 Stead, A.G. *see* Koch, K.M.  
 Steen, K.V. *see* Pierik, M.  
 Stein, J. *see* Bott, C.  
 Stein, J. *see* Schröder, O.  
 Stenson, W.F. *see* Goldstein, J.L.  
 Stephenson, T.J. *see* Kelty, C.J.  
 Sterling, R.K., Salvatori, J.J., Luketic, V.A., Sanyal, A.J., Fulcher, A.S., Stravitz, R.T., Contos, M.J., Mills, A.S. & Schiffman, M.L. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycochenolate moftet in the treatment of primary sclerosing cholangitis, 943  
 Stern, R.C. *see* Konstan, M.W.  
*steroid dependency*, 161  
*steroids*, 143, 151  
 Stessman, M. *see* Ozturk, R.  
 Stevens, J.E. *see* Russo, A.  
 Stevens, T. *see* Reilly, M.C.  
 Stevens, T., Achkar, J.P., Easley, K., Brzezinski, A. & Lashner, B. Azathioprine formulation optimizes metabolite profile in inflammatory bowel disease, 601  
 Stockbrugger, R.W. *see* Ryan, B.M.  
 Stockbrügger, R.W. *see* Wolters, F.L.  
 Stoddard, C.J. *see* Kelty, C.J.  
*stool antigen test*, 469  
 Stravitz, R.T. *see* Sterling, R.K.  
*stroke*, 73  
 Such, J. *see* Zapater, P.  
 Sugitani, M. *see* Kato, K.  
 Suissa, A. *see* Eliakim, R.  
 Sung, J.J.-Y. *see* Wong, V.W.-S.  
 Sung, J.J.Y., Leung, W.K., Ching, J.Y.L., Lao, L., Zhang, G., Wu, J.C.Y., Liang, S.M., Xie, H., Ho, Y.P., Chan, L.S., Berman, B. & Chan, F.K.L. Agreements among traditional Chinese medicine practitioners in the diagnosis and treatment of irritable bowel syndrome, 1205  
*supply and demand*, 507  
*surgery*, 1115  
*survey*, 551  
*sustained virological response*, 931  
 Sutherland, M. *see* Blacka, J.  
 Suzuki, H. *see* Suzuki, M.  
 Suzuki, K. *see* Suzuki, M.  
 Suzuki, M., Maruyama, K., Suzuki, H., Tanaki, S., Suzuki, K. & Ishii, H.  $^{13}\text{C}$ -ethanol breath test reveals impaired alcohol metabolism in patients with *Helicobacter pylori* infection, 109  
 Svedberg, L.-E. *see* Wilder-Smith, C.H.  
 Symmons, D. *see* Forrest, K.  
*symptom assessment*, 891  
*symptomatic postoperative recurrence*, 959  
*symptoms*, 1105  
*systematic review*, 373, 733  
 Szilagyi, A. *see* Fallone, C.A.  
 Tabangin, M. *see* Chand, N.  
 Takahashi, D. *see* Yamamoto, T.  
 Takahashi, Y. *see* Amano, Y.  
 Talley, N.J. *see* Armstrong, D.  
 Talley, N.J. *see* Esllick, G.D.  
 Talley, N.J. *see* Nandurkar, S.  
 Tampieri, A. *see* Gatta, L.  
 Tan, A.C.I.T.L. *see* Bovenschen, H.J.  
 Tanaki, S. *see* Suzuki, M.  
 Tanser, L. *see* Fallone, C.A.  
 Taschieri, A.M. *see* Parente, F.  
*tegaserod*, 213  
 Thabane, M. *see* Marshall, J.K.  
*therapeutic thoracentesis*, 271  
 Thomas, G.A.O. *see* Ingram, J.R.  
 Thompson, M. *see* Rabeneck, L.  
*threshold analysis*, 939  
*thrombocytopenia*, 917  
 van Tilburg, A.J.P. *see* West, R.L.  
 Tindberg, Y., Casswall, T.H., Blennow, M., Bengtsson, C., Granström, M. & Sörberg, M. *Helicobacter pylori* eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial, 295  
*TNF-alpha*, 289  
 Tobias, J.H., Sasi, M.R., Greenwood, R. & Probert, C.S.J. Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy, 951  
 Toffanin, E. *see* Briani, C.  
*tolerance phenomenon*, 559  
 Torgerson, S. *see* Harrison, S.A.  
*toxic hepatitis*, 373  
*traditional Chinese medicine*, 1205  
*transjugular intrahepatic portosystemic shunt*, 271, 867  
*treatment response*, 891  
*treatment with lamivudine*, 281  
*treatment*, 15, 295  
 Triadafilopoulos, G. *see* Gerson, L.B.  
*trial design*, 423  
 Trojan, J. *see* Kerber, A.  
 Trout, J.R. *see* Konstan, M.W.  
 Tsai, H.H., Chapman, R., Shepherd, A., McKeith, D., Anderson, M., Vearer, D., Duggan, S. & Rosen, J.P. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study, 657  
 Tseng, H.-H. *see* Chen, A.  
 Tsibouris, P., Hendrickse, M.T. & Isaacs, P.E.T. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma, 645

tube failure, 875  
 tumor marker, 983  
 Tunturi-Hihmala, H. *see* Armstrong, D.  
 Turner, M. *see* Whitehead, W.E.  
 Tytgat, G.N.J. *see* de Wit, N.J.

ulcer complications, 527  
 ulcerative colitis, 143, 161, 1133, 1143  
 Ullah, N. *see* Gerson, L.B.  
 Umegae, S. *see* Yamamoto, T.  
 Umesaki, Y. *see* Kato, K.  
 urea breath test, 117, 1001  
 ursodeoxycholic acid, 943  
 utilities, 1161

vaccine, 1053  
 Vaira, D. *see* Gatta, L.  
 Vakil, N. *see* Guda, N.  
 Vakil, N., Lanza, F., Schwartz, H. & Barth, J. Seven-day therapy for *Helicobacter pylori* in the United States, 99  
 valdecoxib, 527  
 validity, 891  
 Van Gossum, A. *see* Franchimont, N.  
 Van Gossum, M. *see* Delwaide, J.  
 Van Vlierberghe, H. *see* Delwaide, J.  
 Vandewalle, P. *see* Annese, V.  
 Vandvik, P.O., Wilhelmsen, I., Ihlebæk, C. & Farup, P.G. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications, 1195  
 Varma, R.R. *see* Saeian, K.  
 vascular disease, 73  
 Vearer, D. *see* Tsai, H.H.  
 Venables, T. *see* Armstrong, D.  
 Verburg, K.M. *see* Goldstein, J.L.  
 Vermeire, S. *see* Franchimont, N.  
 Vermeire, S. *see* Pierik, M.  
 Verspaget, H.W. *see* Gao, Q.  
 veteran, 629  
 Vijan, S., Inadomi, J., Hayward, R.A., Hofer, T.P. & Fendrick, A.M. Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the United States, 507  
 viral kinetics, 825  
 viramidine, 917  
 visceral sensitivity, 89  
 visual analogue scale, 1161  
 vitamin E, 1189  
 vitamins, 1029  
 Vlietinck, R. *see* Pierik, M.  
 volume of distribution, 825  
 Von Korff, M. *see* Whitehead, W.E.

Wagener, J.S. *see* Konstan, M.W.  
 Wain, E. *see* Delwaide, J.  
 Wakil, G. *see* Fallone, C.A.  
 Walker, A. *see* Winter, J.  
 Wall, G.C. *see* Feyen, B.  
 Wallace, M.B. *see* Wolfsen, H.C.  
 Wallander, M.-A. *see* Ruigómez, A.

Wallin, L. *see* Madsen, L.G.  
 Wang, J.D. *see* Gu, Q.  
 Wang, W.H. *see* Gu, Q.  
 Ware, J.C. *see* Chand, N.  
 Wassell, J.J. *see* Dolwani, S.  
 Weber, F.T. *see* Delvaux, M.  
 Weersma, R.K., Peters, F.T.M., Oostenbrug, L.E., van den Berg, A.P., van Haastert, M., Ploeg, R.J., Posthumus, M.D., Homan van der Heide, J.J., Jansen, P.L.M. & van Dullemen, H.M. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases, 843  
 weight loss, 623  
 West, J. *see* Boulton-Jones, J.R.  
 West, J. *see* Card, T.R.  
 West, J., Logan, R.F.A., Card, T.R., Smith, C. & Hubbard, R. Risk of vascular disease in adults with diagnosed coeliac disease: a population-based study, 73  
 West, R.L., van der Woude, C.J., Hansen, B.E., Felt-Bersma, R.J.F., van Tilburg, A.J.P., Drapers, J.A.G. & Kuipers, E.J. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study, 1329  
 Wheeler, C. *see* Fallone, C.A.  
 Whitehead, W.E., Levy, R.L., Von Korff, M., Feld, A.D., Palsson, O.S., Turner, M. & Drossman, D.A. The usual medical care for irritable bowel syndrome, 1305  
 Wichers, M. *see* Ryan, B.M.  
 Wiklund, I. *see* Fallone, C.A.  
 Wiklund, I. *see* Labus, J.S.  
 Wilder-Smith, C.H., Röhss, K., Bondarov, P., Hallerbäck, B., Svedberg, L.-E. & Ahlbom, H. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study, 1099  
 Wilhelmsen, I. *see* Vandvik, P.O.  
 Winter, J., Walker, A., Shapiro, D., Gaffney, D., Spooner, R.J. & Mills, P.R. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease, 593  
 Winter, T.A., Wright, J., Ghosh, S., Jahnsen, J., Innes, A. & Round, P. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study, 1337  
 wireless capsule endoscopy, 189  
 Wiseman, M. *see* Nair, S.  
 de Wit, N.J., de Boer, W.A., Geldof, H., Hazelhoff, B., Bergmans, P., Tytgat, G.N.J. & Smout, A.J.P.M. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does *Helicobacter pylori* infection affect proton pump inhibitor effectiveness?, 451  
 Wittman, E.M. *see* Bovenschen, H.J.  
 Wohl, M.E.B. *see* Konstan, M.W.  
 Wolfsen, H.C., Hemminger, L.L., Wallace, M.B. & DeVault, K.R. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer, 1125  
 Wolters, F.L., Russel, M.G.V.M. & Stockbrügger, R.W. Systematic review: has disease outcome in Crohn's disease changed during the last four decades?, 483

women, 551

Wong, B.C.-Y. *see* Gu, Q.

Wong, B.C.Y. *see* Wong, W.M.

Wong, V.W.-S., Chan, H.L.-Y., Hui, A.Y., Chan, K.-F., Liew, C.-T., Chan, F.K.-L. & Sung, J.J.-Y. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese, 45

Wong, W.M. *see* Gu, Q.

Wong, W.M., Lai, K.C., Lam, K.F., Hui, W.M., Huang, J.Q., Xia, H.H.X., Hu, W.H.C., Lam, C.L.K., Chan, C.K., Lam, S.K. & Wong, B.C.Y. Onset and disappearance of reflux symptoms in a Chinese population: a 1-year follow-up study, 803

Wooff, D. *see* Raghunath, A.S.

work absenteeism, 909

work productivity, 459

van der Woude, C.J. *see* West, R.L.

WPAL, 459

Wright, J. *see* Winter, T.A.

Wu, J.C.Y. *see* Sung, J.J.Y.

Xia, H.H.-X. *see* Gu, Q.

Xia, H.H.X. *see* Wong, W.M.

Xie, H. *see* Sung, J.J.Y.

Yagci, R.V. *see* Özgenç, F.

Yaghoobi, M. *see* Mikaeli, J.

Yamada, Y. *see* Yamamoto, T.

Yamamoto, T., Umegae, S., Kitagawa, T., Yasuda, Y., Yamada, Y., Takahashi, D., Mukumoto, M., Nishimura, N., Yasue, K. & Matsumoto, K. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study, 783

Yamaoka, Y. *see* Chen, A.

Yassin, K. *see* Eliakim, R.

Yasuda, Y. *see* Yamamoto, T.

Yasue, K. *see* Yamamoto, T.

YMDD mutants, 281

Yong, A. *see* Dolwani, S.

Younger, H.M., Bathgate, A.J. & Hayes, P.C. Review article: nucleoside analogues for the treatment of chronic hepatitis B, 1211

Yuen, M.F. *see* Gu, Q.

Yuki, T. *see* Amano, Y.

van der Zaag-Loonen, H.J. *see* Afzal, N.A.

van Zanten, S.J.O. *see* Fallone, C.A.

van Zanten, S.V. *see* Fischbach, L.A.

Zapater, P., Lasso de la Vega, M.C., Horga, J.F., Such, J., Frances, R., Esteban, A., Palazón, J.M., Carnicer, F., Pascual, S. & Pérez-Mateo, M. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status, 29

Zara, G. *see* Briani, C.

Zelnac/Zelnorm, 213

Zentilin, P. *see* Frazzoni, M.

Zgouras, D. *see* Kerber, A.

Zhang, G. *see* Sung, J.J.Y.

Zimmerman, J. Irritable bowel, smoking and oesophageal acid exposure: an insight into the nature of symptoms of gastro-oesophageal reflux, 1297

Zinsmeister, A.R. *see* Bharucha, A.E.

Zinsmeister, A.R. *see* Nandurkar, S.

Zocco, M.A. *see* Nista, E.C.

Zubaidi, S. *see* Rodriguez-Stanley, S.

Zubillaga, M. *see* Salgueiro, J.

